SCHEMBL6895667

SCHEMBL6895667

CC(C)(NC(=O)N(CCO)CCC1CCCCC1)C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 1/20 0.37
PPARA Q07869 7/20 0.37
PPARG P37231 6/20 0.37
PPARD Q03181 3/20 0.37
MAPT P10636 2/20 0.37
CASR P41180 1/20 0.37
GMNN O75496 1/20 0.37
USP2 O75604 1/20 0.37
USP1 O94782 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
CYP1A2 P05177 1/20 0.37
POLB P06746 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
ALOX15 P16050 1/20 0.37
NFKB1 P19838 1/20 0.37
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6890137 0.86 CNR2 (0.38) PPARAPPARGPPARDMAPTCASR
SCHEMBL27570927 0.81 PPARA (0.36) PPARAPPARGPPARDMAPTCASR
SCHEMBL6898335 0.80 CNR1 (0.36) CASRALDH1A1LMNATP53CNR1
SCHEMBL4667724 0.77 KDM5A (0.40) CASRALDH1A1TDP1KDM5APHF8
SCHEMBL6894998 0.77 LTA4H (0.42) PPARAPPARGPPARDMAPTCASR
SCHEMBL6897064 0.77 LTA4H (0.42) PPARAPPARGPPARDMAPTCASR
SCHEMBL6897170 0.77 LTA4H (0.42) PPARAPPARGPPARDMAPTCASR
SCHEMBL27538245 0.76 HSD17B10 (0.36) PPARAPPARGPPARDMAPTCASR
SCHEMBL6731438 0.75 PKM (0.41) CASRALDH1A1LMNACNR1CNR2
SCHEMBL6896957 0.75 LTA4H (0.40) CASRPOLBKDM5APHF8KDM2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6730784-B2 AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-05-04 US disclosed
US-20020198376-A1 Novel urea derivatives SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-26 US disclosed
US-6492370-B1 Urea derivatives and pharmaceutical compositions thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-10 US disclosed
CN-1299344-A Novel urea derivatives SANTEN PHARCEUMATICAL CO LTD (JP) 2001-06-13 CN disclosed
EP-1072591-A1 NOVEL UREA DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198376-A1 Novel urea derivatives TNF, CTH, CFH CXCR2 200/4885PPARA 3847/4885PPARG 3342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.